The migratory properties of IGF-1 are upregulated and correlated with epithelial–mesenchymal transition (EMT) markers in MM patients, which provides proof of the potential use of this growth factor in MM treatment [134]. This evidence concerns the gene IGF1 and Miyoshi myopathy.